BioSpace News Archive

Medivir AB announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma has been published in JAMA Dermatology by Kilgour, JM et al.

Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, announced it has raised $370 Million in a Series B financing to advance the development of its novel drug generation platform.

Clover Biopharmaceuticals, Ltd., a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates, and CEPI, the Coalition for Epidemic Preparedness Innovations, announced that CEPI will provide up to an additional US$36.9 million in funding to support continued development of SCB-2019 through licensure.

Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, announced new interim data published from the large multi-center observational registry study INSIGHT utilizing its novel predictive and prognostic blood-based host immune classifier to stratify Immune checkpoint inhibition treatment response in patients with advanced non-small cell lung cancer.

Itamar Medical Ltd., a leading medical device and digital health company focused on the integration of sleep apnea management into the cardiac patient care pathway, reported unaudited financial results for the third quarter of 2021.

Immuneering Corporation announced that Ben Zeskind, Ph.D., Co-Founder, President and Chief Executive Officer of Immuneering, Biren Amin, MBA, Chief Financial Officer and Brett Hall, Ph.D., Chief Scientific Officer, will participate in several December investor conferences to share commentary with investors around the Company’s pipeline, platform and business strategy.

Centogene N.V. today announced that it will issue its financial results for the quarter ended September 30, 2021, on Wednesday, November 24, 2021, and will host a conference call and webcast to discuss these results at 2 p.m. CET / 8 a.m. ET that day.

Caris Life Sciences® announced today that the Herbert Irving Comprehensive Cancer Center (HICCC) has joined Caris’ Precision Oncology Alliance™ (POA).

Epizyme, Inc. today announced two appointments to the Company’s Board of Directors: clinical oncology executive, Roy A. Beveridge, M.D., and international pharmaceutical and financial executive, Carol Stuckley, M.B.A.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, has announced it was named a winner in the MedReps.com Best Places to Work in Medical Sales 2022 survey, earning the Number 1 spot for large companies and making this the fifth consecutive year the company has been on the list.